Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study

• DOI: 10.1111/liv.14170
• Publication Date: 2019-06-08T05:34:28Z
• Authors: Marcello Persico; Andrea Aglitti; Michele Milella; Carmine Coppola; Vincenzo Messina; Ernesto Claar; Ivan Gentile; Fernando Sogari; Paola Pierri; Lorenzo A. Surace; Filomena Morisco; Paolo Tundo; Giuseppina Branca...; Gaetano Serviddio; Pietro Gatti; Antonio P. Termite; Giovan G. Di Cost...; Benedetto Caroleo; Raffaele Cozzolongo; Nicola Coppola; Annamaria Longo; Luca Fontanella; Alessandro Federico; Valerio Rosato; Irene Terrenato; Mario Masarone
• Keywords: Hepatitis C

It is paramount to identify predictors of treatment failure with direct antiviral agents in 'field-practice' patients, including people who inject drugs (PWID). Data on the efficacy glecaprevir/pibrentasvir (GLE/PIB) a field-practice scenario are scant. The multicentre MISTRAL study enrolled 1177 PWID, assess real-life and safety GLE/PIB predictive factors for this treatment.This was prospective, longitudinal study. outcome variable rate sustained virological response (SVR) at week 12.A total 123 patients (10%) were infected from hepatitis C virus (HCV) 3. METAVIR fibrosis score F4 104 subjects (9%); 118 PWID. Overall, 1163/1177 (99%) achieved SVR. baseline clinical discriminating between success age (P = 0.031) creatinine level 0.034). SVR rates not influenced by gender, substance abuse, previous treatment, duration, or chronic kidney disease stage. Compared non-substance users, PWID exhibited significantly different genotype pattern distribution (χ2 < 0.001). A 40/118 (33.9%) users HCV3 compared 83/1056 (7.9%) users. Only 6 (0.5%) reported serious adverse event.The provides evidence highly epidemic HCV area southern Italy; it unveiled significant differences among most underserved difficult-to-treat patient subgroups